ICYMI: Drug Topics July/August 2024 Issue

These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.

With minimal pharmacological treatments coming to market for chronic pain, researchers have explored new technologies for advancing pain treatment across the globe.

Approximately, 62% of respondents stated that the number of active drug shortages could potentially increase by more than 25% within the next 5 years.

Join Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, for the first episode of Dispensing Leadership, a new podcast from Drug Topics® and RPhAlly.

Ensitrelvir demonstrated a 67% relative risk reduction of developing symptomatic COVID-19 in household contact patients.

Deucravacitinib (Sotyktu) also demonstrates improvements in signs and symptoms, extra-articular manifestations, and patient-reported outcomes.